Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
ISSN: 2155-9899
Zeiad Gad
Posters-Accepted Abstracts: J Clin Cell Immunol
Micro-RNAs (miRs) are known to be differentially expressed in the serum of cancer patients and controls, and can thus be used as biomarkers for cancer screening. We detected the expression level of miR-29b-2, 155, 197 and 205 in the serum of female breast cancer patients and healthy controls to detect whether serum level of this chosen micro-RNAs could detect patients with breast cancer and also to detect difference in level of microRNAs between non-metastatic cases and metastatic cases, also we tried to detect any relation between level of micro-RNAs and the stage of the tumor, the size of tumor, nodal affection, the presence of metastasis and also the site of metastasis. Serum samples were collected from 130 female patients, 80 with non-metastatic breast cancer, 20 with metastatic breast cancer and 30 healthy controls. Real-time quantitative PCR was used to detect the expression level of miR-29b-2, �??155, �??197 and �??205. The expression level of miR-29b-2, �??155, �??197 and �??205 was significantly increased in the serum of breast cancer patients. We detected statistical significance in expression of the different types of micro-RNAs in relation to tumor size, expression is higher in T3 than in T2 cases. We detected statistical significance in expression of the different types of micro-RNAs in relation to nodal affection, expression is higher in N3 than N2. miR-29b-2, �??155, �??197 and �??205 may be useful as a blood-based biomarker for breast cancer screening.